Trial Profile

The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX-629 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions
Acronyms ADRO
Sponsors Aldeyra Therapeutics

Most Recent Events

01 Nov 2024 Status changed from recruiting to completed.
19 Dec 2023 Results published in the Aldeyra Therapeutics Media Release
18 Dec 2023 According an Aldeyra Therapeutics media release, company will host a webcast and conference call on Tues, 19 Dec, 2023, at 8:00 am, to provide top-line results from this Phase 2 clinical trial of ADX-629 in patients with atopic dermatitis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com